

Errata to Combined FDA and Applicant ODAC Briefing Document

Oncologic Drugs Advisory Committee (ODAC) Meeting

July 14, 2020

BLA# 761158

Drug Name: Belantamab Mafodotin

Applicant: GlaxoSmithKline Intellectual Property Development Ltd. England

Errata to Combined FDA and Applicant ODAC Briefing Document

ODAC Meeting

July 14, 2020

This document is an erratum to the original combined FDA and Applicant ODAC Briefing Document. The erroneous text is followed by the correction in bold below.

1. Page 85, Appendix Section 9.4.6 *Dose Justification*, Figure 15 footnote, text below:
2. Page 86, Appendix Section 9.4.6 *Dose Justification*, Figure 16 footnote, text below:
3. Page 87, Appendix Section 9.4.6 *Dose Justification*, Figure 18 footnote, text below:

Original text:

Source: FDA Analysis

Corrected to read as:

Source: **Applicant's analysis, confirmed by FDA**